Hair typically starts falling out two to three weeks after your first chemotherapy infusion, though some people notice shedding as early as seven to ten days. The timeline varies by drug, dosage, and individual factors, but most people see significant loss within the first month of treatment.
The Typical Shedding Timeline
Most oncologists cite two to three weeks after the first treatment cycle as the standard window for hair loss to begin. Some research puts the onset earlier, at seven to ten days. In rare cases, shedding has been documented as soon as four to five days after the first infusion, particularly with certain taxane drugs. Once it starts, the shedding typically continues over the following two to three weeks, meaning you could go from a full head of hair to significant thinning or near-complete loss within about a month of your first treatment.
The speed catches many people off guard. Hair may come out in clumps on your pillow, in the shower, or when you run your fingers through it. For most people receiving high-risk drugs, the loss is diffuse rather than patchy, affecting the entire scalp relatively evenly.
Signs That Shedding Is About to Start
Before hair actually falls out, many people experience physical warning signs. Your scalp may feel tender, itchy, or sensitive to the touch. Some describe a tingling or soreness, almost like the hair hurts. These sensations often appear a day or two before the shedding becomes visible, giving you a brief heads-up to prepare emotionally and practically.
Why Chemotherapy Causes Hair Loss
Chemotherapy targets rapidly dividing cells, which is effective against cancer but also affects other fast-growing cells in the body. Hair follicles are among the most active: roughly 85% to 90% of scalp hair follicles are in their active growth phase at any given time. When chemo drugs reach these follicles, they trigger a process of cell death that disrupts normal hair production. The hair shaft weakens at the root and breaks off or falls out entirely. This type of loss is called anagen effluvium, and it happens because the follicle was actively growing when the drug hit it.
Scalp and beard hair are the most affected because they have the highest rate of cell division. Hair on your arms, legs, and other areas divides more slowly, so it’s less vulnerable, though not immune.
Eyebrows, Eyelashes, and Body Hair
Scalp hair falls out first and most dramatically because its growth phase lasts two to six years, meaning nearly all follicles are active and exposed. Eyelashes have a much shorter growth cycle of about one to one and a half months, so a smaller percentage of follicles are in the vulnerable phase at any given time. Eyebrows fall somewhere in between.
In practice, eyebrow and eyelash loss usually lags behind scalp hair by several weeks. Some people lose them partially, others more completely, and some retain them throughout treatment. One case documented in medical literature showed a patient with complete scalp hair loss and partial eyebrow loss about four weeks after finishing chemotherapy, while her eyelashes remained intact. Your experience will depend heavily on the specific drugs used and how many treatment cycles you receive.
Your Drug Regimen Matters
Not all chemotherapy causes the same degree of hair loss. Taxane-based drugs and anthracyclines carry the highest risk for significant or complete loss. Among taxanes, docetaxel is associated with more severe and prolonged hair loss than paclitaxel. Women tend to experience more intense, visible shedding than men, partly because men with pre-existing thinning have fewer actively growing follicles for the drugs to affect.
Some lower-intensity regimens cause only mild thinning that may not even be noticeable to others. Your oncologist can generally tell you before treatment begins whether your specific regimen is likely to cause noticeable hair loss, significant loss, or potentially none at all.
Cold Caps Can Reduce Hair Loss
Scalp cooling systems, often called cold caps, work by constricting blood vessels in the scalp during infusion, reducing how much of the drug reaches your hair follicles. The results can be meaningful: in a retrospective study of one cold cap system, the median amount of hair retained was 75%, and 92% of patients kept at least half their hair.
Success rates vary by drug. Patients on paclitaxel-containing regimens retained favorable amounts of hair about 96% of the time, while those on doxorubicin-containing regimens saw favorable results about 71% of the time. Cold caps require wearing a tight, very cold device for hours during and after each infusion, which some people find uncomfortable. They also work better for some hair types than others, with slightly lower success rates reported for non-Caucasian patients.
When Hair Grows Back
For most people, new growth begins within a few weeks to a couple of months after the final treatment. The first growth is often fine, soft peach fuzz. Over the following months, it gradually thickens and lengthens. Many people notice texture or color changes: hair that was straight may grow back curly, or the color may be slightly different. These changes are usually temporary, and hair often returns to its pre-treatment character within a year or two, though this isn’t universal.
The Risk of Permanent Hair Loss
Most chemotherapy-related hair loss is temporary, but a small percentage of people experience persistent or permanent thinning. This is defined as incomplete or absent regrowth six months after finishing treatment. Taxane-based drugs carry the highest risk: in one UK study, about 10% of patients on paclitaxel and 23% of patients on docetaxel reported persistent hair loss. Higher cumulative doses increase the risk. In a Spanish study, 35% to 52% of patients receiving higher doses of docetaxel had some degree of lasting thinning.
Permanent loss can also affect eyebrows and eyelashes. Among patients who received docetaxel, over half reported partial eyebrow regrowth and about 42% reported partial eyelash regrowth. Older age, particularly being post-menopausal, is associated with higher risk. There also appears to be a genetic component, with a specific gene variant linked to nearly four times the odds of permanent loss.
If your hair hasn’t returned to a satisfactory level six months after your last treatment, it’s worth raising the issue with your care team, as there are options that may help stimulate regrowth.